Skip to main content
TFX logo

Teleflex Incorporated (TFX) Stock: Price, Forecast & Analyst Target

Teleflex Incorporated (TFX) — MoonshotScore 61/100 (Fair band), calculated Nov 18, 2026. Price $161.58 (-1.11%), as of the Nov 20, 2026 trading session; market cap $6.41B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$161.58 −$1.82 (-1.11%) Market Cap $6.41B

Teleflex Incorporated · TFX · NYSE · Healthcare · Medical - Instruments & Supplies

Research dated 2026-09-13: Teleflex manufactures single-use medical devices for surgical, interventional, and critical-care settings, with a portfolio spanning vascular access catheters, interventional cardiology tools, and anesthesia equipment. The critical question is whether recent operational disruption and margin compression can be reversed, or whether the company faces structural headwinds to profitability.

Price as of Nov 20, 2026

Key Statistics

61 of 100

MoonshotScore v2 · Teleflex (TFX)

Fair
Business Quality Elite (80)
Financial Safety Strained (36)
Valuation Fair (63)
Growth Durability Flat (50)
Momentum Surging (92)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet; the market is already moving on it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $567M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 2.86 · Piotroski F 7

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TFX (58 recorded, newest six shown)
RecordedScoreBand
56Fair
56Fair
56Fair
61Fair
61Fair
61Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$161.58
Change on the day-1.11%
52-week range$100.18–$161.58
Market capitalisation$6.41B—
Price / earnings (trailing)19.18
Shares traded on the day655.0K
Beta (volatility vs the S&P 500)0.83

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $103, high $162, latest $162. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $162 $103 high $162 Feb 26, 2026 · Earnings results · reported below the recorded estimate · close $1221May 7, 2026 · Earnings results · reported above the recorded estimate · close $1332Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $1353Nov 5, 2026 · Earnings results · reported above the recorded estimate · close $1514 Oct 17, 2025 Nov 20, 2026 · $162 $128Oct 17, 2025$124Oct 31, 2025$107Nov 14, 2025$114Nov 28, 2025$127Dec 12, 2025$123Dec 26, 2025$113Jan 9, 2026$103Jan 23, 2026$108Feb 6, 2026$115Feb 20, 2026$113Mar 6, 2026$105Mar 20, 2026$118Apr 2, 2026$132Apr 17, 2026$122May 1, 2026$130May 15, 2026$129May 29, 2026$130Jun 12, 2026$130Jun 26, 2026$136Jul 10, 2026$132Jul 24, 2026$135Aug 7, 2026$139Aug 21, 2026$138Sep 4, 2026$125Sep 18, 2026$124Oct 2, 2026$130Oct 16, 2026$140Oct 30, 2026$155Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Teleflex (TFX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Debt/Equity Neutral
ROE Weak
Gross Margin Moderate

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Teleflex (TFX), and what does it report?

Short answer · as of

Teleflex's reported revenue measures the volume of single-use devices sold to hospitals, clinics, and healthcare provider networks.

The quarterly earnings reflect both volume growth and pricing power, minus the cost of goods sold and substantial selling and distribution expenses required to reach hospital buyers across different product categories. The company operates through distinct business units—Vascular Access, Interventional Cardiology, Surgical, and Respiratory—each serving different customer sets.

What the numbers measure is the company's ability to maintain market share in markets where it competes against both large diversified device companies and nimble specialists. Gross margins reveal pricing discipline; operating margins show whether administrative costs are controlled as the company scales. The reported net result has been volatile in recent periods, reflecting both operational challenges and significant charges related to acquisitions and restructuring.

2 · Latest results

What do the latest results show for Teleflex (TFX)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $567M.

Recent results show a company in transition, with large operating losses in the most recent fiscal year despite positive gross margins on product sales. The latest quarterly earnings improved substantially, suggesting the worst of the operational disruption may be past. However, net margins remain deeply negative on a trailing-twelve-month basis, indicating that the recovery is incomplete.

Management's outlook emphasizes margin expansion ahead, with expectations that cost reduction initiatives and operating leverage will drive profitability recovery. The company cautioned on near-term revenue growth, suggesting it is prioritizing profitable growth over volume. The strategy appears to be to streamline operations, divest lower-margin business units, and focus on core high-value products where the company has defensible positions.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$567.78M Nov 5, 2026
Latest report · revenue estimate
$565.52M Nov 5, 2026
Latest report · revenue vs estimate
Above estimate Nov 5, 2026
Latest report · EPS vs estimate
Above estimate Nov 5, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 5, 2026$567.78M$565.52M$2.6300$1.9000
Aug 6, 2026$570.30M$559.59M$1.7600$1.2800
May 7, 2026$548.26M$536.91M$1.3900$1.2100
Feb 26, 2026$569.00M$919.31M$1.9300$3.7300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$567M-$409M-$9.24 (diluted)
Q4 FY2025-$402M-$714M-$16.15 (diluted)
Q1 FY2026$548M-$8M-$0.18 (diluted)
Q2 FY2026$570M$100M$2.28 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Teleflex (TFX)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Teleflex carries significant debt relative to its size, with total debt substantially exceeding cash and short-term investments. The debt-to-equity ratio exceeds one, indicating the company is leveraged beyond typical manufacturing norms. Operating cash flow is positive, allowing the company to service debt and fund operations, but free cash flow is constrained by capital expenditure requirements and interest expenses.

The principal risks are near-term: if operational improvements do not materialize, the leverage position becomes dangerous. The company is also exposed to hospital consolidation and pricing pressure, as healthcare systems increasingly demand volume discounts. A recession in elective procedures would reduce demand immediately. Long-term, the business is sound, but the next quarters will determine whether the company successfully executes its turnaround or faces a credit downgrade.

4 · What to check next?

What should you watch next at Teleflex (TFX)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

Watch for quarterly operating margin trends and management's disclosure of restructuring completion and annualized savings. These will signal whether the operational improvement is real or temporary. Monitor revenue growth rates by segment, as a slowdown in Vascular Access—the largest segment—would undermine the turnaround narrative.

Track the company's debt refinancing activity and whether management provides updated profitability targets. Analyst sentiment and rating agency commentary will reveal whether the financial community believes the turnaround is credible. Hospital capital spending and elective procedure volumes are leading indicators of Teleflex's demand environment—weakness there would validate near-term caution on the company's prospects.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Teleflex compare with its peers?

Short answer

Teleflex's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Teleflex differs from competitors through its breadth—it operates across multiple distinct device categories, which provides customer relationships that specialists lack. The company sells into hospital surgical suites, interventional cardiology labs, and critical-care units, creating touchpoints that allow cross-selling. However, this breadth also creates complexity and redundancy in operations compared with focused competitors.

The company's competitive position varies by product line. In Vascular Access, it maintains a strong position with the Arrow brand. In Interventional Cardiology, it competes against larger diversified players with deeper pockets. The Surgical and Respiratory divisions face similar dynamics. The strength of Teleflex relative to both pure diversified device companies and specialist operators remains unproven in this turnaround phase—execution will determine whether the broad portfolio is an advantage or a liability.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Krystal Biotech, Inc. (KRYS) Named competitor$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Haemonetics Corporation (HAE) Same industry, near in market value$120.16 Nov 20, 2026$5.47B83 5-pillar Nov 18, 2026
Merit Medical Systems, Inc. (MMSI) Same industry, near in market value$84.34 Nov 20, 2026$5.05B81 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Same industry, near in market value$140.08 Nov 20, 2026$8.88B77 5-pillar Nov 18, 2026
ICU Medical, Inc. (ICUI) Same industry, near in market value$172.52 Nov 20, 2026$4.31B73 5-pillar Nov 18, 2026
Stevanato Group S.p.A. (STVN) Same industry, near in market value$15.65 Nov 20, 2026$4.27B73 5-pillar Nov 18, 2026
Avantor, Inc. (AVTR) Same industry, near in market value$14.84 Nov 20, 2026$10.1B71 5-pillar Nov 18, 2026
Repligen Corporation (RGEN) Same industry, near in market value$163.81 Nov 20, 2026$10.5B71 5-pillar Nov 18, 2026
Teleflex (TFX) — this page$161.58$6.41B61
Vaxcyte, Inc. (PCVX) Named competitor$55.39 Nov 20, 2026$8.77B51 5-pillar Nov 18, 2026
The Cooper Companies, Inc. (COO) Same industry, near in market value$58.88 Nov 20, 2026$11.2B40 5-pillar Nov 18, 2026
Alkermes plc (ALKS) Named competitor$44.94 Nov 20, 2026$7.55B35 5-pillar Nov 18, 2026
Bausch + Lomb Corporation (BLCO) Same industry, near in market value$20.69 Nov 19, 2026$7.40B35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$158.00 – $170.00
Consensus target
$162.33
Median target
$160.00

Consensus record · Captured .

Measured against a quoted price of $161.58 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 8, 2026

Transactions
8
Identified insiders
3
Purchases
0
Sales
0
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TFX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Baupost GroupSeth KlarmanQ3 20260%$0Sold out (was $178.60M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Teleflex (TFX)?

Read these with our analysis →

TFX Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

What is the Arrow brand and why is it important to Teleflex?

Arrow is a recognized brand of vascular access catheters and related devices used in critical care and surgery. It represents decades of market share and clinical preference. The Arrow brand generates the largest share of Teleflex revenue and anchors customer relationships, making it the company's most defensible asset.

Why did Teleflex's profitability collapse so suddenly?

The company acquired Artis Medical and Vascular Solutions, integrating them while simultaneously dealing with supply chain disruption and manufacturing challenges. Integration costs, purchase accounting adjustments, and operational missteps created large losses. Additionally, hospitals reduced elective procedures, pressuring demand.

What is the UroLift System and what market does it serve?

UroLift is an implantable device for treating lower urinary tract symptoms from benign prostatic hyperplasia—enlarged prostate in aging men. It offers a less invasive alternative to surgical removal, creating a recurring revenue stream as the population ages. The device represents a higher-margin business within the company's portfolio.

Does Teleflex's turnaround depend on acquiring or divesting units?

Management has signaled focus on core, profitable product lines and has divested or is evaluating divestiture of lower-margin assets. The turnaround strategy appears to emphasize operational excellence in existing units rather than additional acquisitions, marking a shift from the growth-by-acquisition approach that created recent challenges.

What is the TFX stock price today?

The last price recorded for Teleflex Incorporated (TFX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TFX price target?

The analyst consensus price target for Teleflex Incorporated (TFX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 43 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Quarterly income statement (USD thousands)
  • 1. What is Teleflex (TFX), and what does it report?: Quarterly income statement (USD thousands); Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Teleflex (TFX)?: Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
  • 3. What are the financial strengths and risks for Teleflex (TFX)?: Cash, investments and debt; Trailing twelve-month ratio set; Cash against market value
  • 4. What should you watch next at Teleflex (TFX)?: Next earnings report; Management outlook — dated call excerpts; Revenue by segment
  • 5. How does Teleflex compare with its peers?: Revenue by segment; Business description; Analyst revenue and earnings estimates (average)
  • FAQ: What is the Arrow brand and why is it important to Teleflex?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: Why did Teleflex's profitability collapse so suddenly?: Annual revenue and net result (USD millions); Management outlook — dated call excerpts; Recent SEC filings
  • FAQ: What is the UroLift System and what market does it serve?: Business description; Revenue by segment; Reported versus estimated, last 8 quarters
  • FAQ: Does Teleflex's turnaround depend on acquiring or divesting units?: Management outlook — dated call excerpts; Recent SEC filings; Analyst revenue and earnings estimates (average)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.